199 related articles for article (PubMed ID: 37185203)
1. Risk Factors for Relapse and/or Prolonged Glucocorticoid Therapy in Polymyalgia Rheumatica: Multicenter Study in 185 Patients.
Vinicki JP; Gut O; Maliandi MDR; Velasco Zamora JL; Linarez M; Cusa MA; Got J; Spinetto MA; Estevez AJ; Brigante A; Curti AC; Costi AC; Cavallasca J
J Clin Rheumatol; 2024 Jan; 30(1):e34-e38. PubMed ID: 37185203
[TBL] [Abstract][Full Text] [Related]
2. Long-term glucocorticoid treatment and high relapse rate remain unresolved issues in the real-life management of polymyalgia rheumatica: a systematic literature review and meta-analysis.
Floris A; Piga M; Chessa E; Congia M; Erre GL; Angioni MM; Mathieu A; Cauli A
Clin Rheumatol; 2022 Jan; 41(1):19-31. PubMed ID: 34415462
[TBL] [Abstract][Full Text] [Related]
3. Long-term glucocorticoid treatment in patients with polymyalgia rheumatica, giant cell arteritis, or both diseases: results from a national rheumatology database.
Albrecht K; Huscher D; Buttgereit F; Aringer M; Hoese G; Ochs W; Thiele K; Zink A
Rheumatol Int; 2018 Apr; 38(4):569-577. PubMed ID: 29124397
[TBL] [Abstract][Full Text] [Related]
4. Longterm therapy in polymyalgia rheumatica: effect of coexistent temporal arteritis.
Narváez J; Nolla-Solé JM; Clavaguera MT; Valverde-García J; Roig-Escofet D
J Rheumatol; 1999 Sep; 26(9):1945-52. PubMed ID: 10493675
[TBL] [Abstract][Full Text] [Related]
5. Polymyalgia Rheumatica and Giant Cell Arteritis: A Systematic Review.
Buttgereit F; Dejaco C; Matteson EL; Dasgupta B
JAMA; 2016 Jun; 315(22):2442-58. PubMed ID: 27299619
[TBL] [Abstract][Full Text] [Related]
6. Effect of Tocilizumab on Disease Activity in Patients With Active Polymyalgia Rheumatica Receiving Glucocorticoid Therapy: A Randomized Clinical Trial.
Devauchelle-Pensec V; Carvajal-Alegria G; Dernis E; Richez C; Truchetet ME; Wendling D; Toussirot E; Perdriger A; Gottenberg JE; Felten R; Fautrel BJ; Chiche L; Hilliquin P; Le Henaff C; Dervieux B; Direz G; Chary-Valckenaere I; Cornec D; Guellec D; Marhadour T; Nowak E; Saraux A
JAMA; 2022 Sep; 328(11):1053-1062. PubMed ID: 36125471
[TBL] [Abstract][Full Text] [Related]
7. The spectrum of polymyalgia rheumatica in northwestern Spain: incidence and analysis of variables associated with relapse in a 10 year study.
González-Gay MA; García-Porrúa C; Vázquez-Caruncho M; Dababneh A; Hajeer A; Ollier WE
J Rheumatol; 1999 Jun; 26(6):1326-32. PubMed ID: 10381051
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoids for Management of Polymyalgia Rheumatica and Giant Cell Arteritis.
Matteson EL; Buttgereit F; Dejaco C; Dasgupta B
Rheum Dis Clin North Am; 2016 Feb; 42(1):75-90, viii. PubMed ID: 26611552
[TBL] [Abstract][Full Text] [Related]
9. PolyMyalgia Rheumatica treatment with Methotrexate in Optimal Dose in an Early disease phase (PMR MODE): study protocol for a multicenter double-blind placebo controlled trial.
Marsman DE; Bolhuis TE; den Broeder N; den Broeder AA; van der Maas A
Trials; 2022 Apr; 23(1):318. PubMed ID: 35428320
[TBL] [Abstract][Full Text] [Related]
10. Comparable Rates of Glucocorticoid-Associated Adverse Events in Patients With Polymyalgia Rheumatica and Comorbidities in the General Population.
Shbeeb I; Challah D; Raheel S; Crowson CS; Matteson EL
Arthritis Care Res (Hoboken); 2018 Apr; 70(4):643-647. PubMed ID: 28704600
[TBL] [Abstract][Full Text] [Related]
11. Relapse in a population based cohort of patients with polymyalgia rheumatica.
Kremers HM; Reinalda MS; Crowson CS; Zinsmeister AR; Hunder GG; Gabriel SE
J Rheumatol; 2005 Jan; 32(1):65-73. PubMed ID: 15630727
[TBL] [Abstract][Full Text] [Related]
12. Incidence of infections associated with oral glucocorticoid dose in people diagnosed with polymyalgia rheumatica or giant cell arteritis: a cohort study in England.
Wu J; Keeley A; Mallen C; Morgan AW; Pujades-Rodriguez M
CMAJ; 2019 Jun; 191(25):E680-E688. PubMed ID: 31235489
[TBL] [Abstract][Full Text] [Related]
13. Polymyalgia Rheumatica and Giant Cell Arteritis: Rapid Evidence Review.
Raleigh MF; Stoddard J; Darrow HJ
Am Fam Physician; 2022 Oct; 106(4):420-426. PubMed ID: 36260899
[TBL] [Abstract][Full Text] [Related]
14. Predicting the risk of relapse in polymyalgia rheumatica: novel insights.
Prieto-Peña D; Castañeda S; Atienza-Mateo B; Blanco R; González-Gay MA
Expert Rev Clin Immunol; 2021 Mar; 17(3):225-232. PubMed ID: 33570454
[TBL] [Abstract][Full Text] [Related]
15. Glucocorticoids Are Not Associated with Bone Mineral Density in Patients with Polymyalgia Rheumatica, Giant Cell Arteritis and Other Vasculitides-Cross-Sectional Baseline Analysis of the Prospective Rh-GIOP Cohort.
Palmowski A; Wiebe E; Muche B; Hermann S; Dejaco C; Matteson EL; Buttgereit F
Cells; 2022 Feb; 11(3):. PubMed ID: 35159345
[TBL] [Abstract][Full Text] [Related]
16. An update on polymyalgia rheumatica.
Lundberg IE; Sharma A; Turesson C; Mohammad AJ
J Intern Med; 2022 Nov; 292(5):717-732. PubMed ID: 35612524
[TBL] [Abstract][Full Text] [Related]
17. Giant cell arteritis and polymyalgia rheumatica: an update.
González-Gay MA; Pina T
Curr Rheumatol Rep; 2015 Feb; 17(2):6. PubMed ID: 25618572
[TBL] [Abstract][Full Text] [Related]
18. Polymyalgia rheumatica and giant cell arteritis in older patients: diagnosis and pharmacological management.
Schmidt J; Warrington KJ
Drugs Aging; 2011 Aug; 28(8):651-66. PubMed ID: 21812500
[TBL] [Abstract][Full Text] [Related]
19. Treatment of polymyalgia rheumatica: a systematic review.
Hernández-Rodríguez J; Cid MC; López-Soto A; Espigol-Frigolé G; Bosch X
Arch Intern Med; 2009 Nov; 169(20):1839-50. PubMed ID: 19901135
[TBL] [Abstract][Full Text] [Related]
20. Efficacy of methotrexate in polymyalgia rheumatica in routine rheumatology clinical care.
Ruediger C; Nguyen L; Black R; Proudman S; Hill C
Intern Med J; 2020 Sep; 50(9):1067-1072. PubMed ID: 32043726
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
